

**S5 Table.** Ongoing anti-angiogenic studies

<b>Study identifier<sup>a)</sup></b>	<b>Trial design/Setting</b>	<b>Disease</b>	<b>Treatment</b>
<b>Bevacizumab</b>			
NCT01191697	Ph II	HER2-positive metastatic esophagogastric cancer	Capecitabine and oxaliplatin, plus bevacizumab and trastuzumab
NCT01359397	Ph II	HER2-positive locally advanced or metastatic gastric cancer or gastroesophageal junction cancer	Docetaxel, oxaliplatin, and capecitabine with bevacizumab and trastuzumab
NCT01471470	Ph II	HER2-negative unresectable advanced gastric cancer	Neoadjuvant chemotherapy with docetaxel, capecitabine, cisplatin, and bevacizumab
<b>Ramucirumab</b>			
NCT02443324	Ph I	Locally advanced and unresectable or metastatic gastric or gastroesophageal junction cancer	Ramucirumab plus pembrolizumab
NCT02359058	Ph Ib	Advanced gastric or gastroesophageal junction cancer	First-line ramucirumab in combination with fluoropyrimidines and platinum-based agents
NCT02539225	Ph II	Metastatic gastric or gastroesophageal junction cancer	S-1 and oxaliplatin with or without ramucirumab as first-line therapy followed by paclitaxel with ramucirumab as second-line therapy
NCT02514551	Ph II	Alternative ramucirumab doses in combination with paclitaxel	Alternative ramucirumab doses in combination with paclitaxel
NCT02443883	Ph II	Second-line gastric or gastroesophageal junction cancer	Four ramucirumab dosing regimens

NCT02314117	Ph III	Metastatic gastric or gastroesophageal junction cancer	First-line capecitabine and cisplatin with or without ramucirumab
NCT02726399	Ph II	Metastatic HER2-positive gastroesophageal junction and gastric cancer	Ramucirumab with trastuzumab and capecitabine/cisplatin
NCT02572687	Ph I	Locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies including gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC)	Ramucirumab in combination with anti-PD-L1 antibody durvalumab
<b>Apatinib</b>			
NCT02529878	Ph II	Unresectable gastric cancer	S-1/paclitaxel chemotherapy plus apatinib
NCT02525237	Ph II	Advanced gastric or gastroesophageal junction cancer	First-line apatinib in combination with S-1
NCT02409199	Ph II/III	Locally advanced or metastatic gastric or gastroesophageal junction cancer	Second-line apatinib versus docetaxel
NCT02510469	Ph II/III	Advanced gastric cancer patients with positive exfoliative cancer cells in peritoneal washes	Maintenance apatinib after adjuvant chemotherapy
NCT02509806	Ph II/III	Recurrent or metastatic gastric cancer	Maintenance apatinib after first-line chemotherapy
NCT02537171	Ph III	Advanced or metastatic gastric or gastroesophageal junction cancer	Maintenance apatinib after first-line treatment
NCT02485015	Ph II	Advanced gastric cancer	Third-line apatinib plus cytokine-induced killer cells
<b>Regorafenib</b>			
NCT02406170	Ph 1b	Advanced esophagogastric carcinoma	Regorafenib in combination with paclitaxel
NCT02241720	Ph II	Metastatic or advanced esophageal, gastroesophageal junction, or gastric cancer	Second-line regorafenib

Ph, phase. <sup>a)</sup>Clinicaltrials.gov study identifier.